Program of the 15th ESLHO Symposium

Registration

Welcome

• Single-cell studies: genomics, epigenomics, transcriptomics & proteomics - TBC
• Advances in high-throughput cost-effective molecular diagnostics - Lennart Kester, Utrecht, NL
• Ultrasensitive combined cellular & molecular diagnostics: Mast cell diseases as a model - Alberto Orfao, Salamanca, ES
• Distinguishing clonal hematopoiesis from pre-leukemic persistence using single-cell DNA methylation - Michael Scherer, Heidelberg, DE
• Abstract based presentation

Coffee break

• Unmet clinical needs in the settings of MRD monitoring in AML (clinical perspective) - Michael Heuser, Halle, DE
• Antigen escape & lineage infidelity in AML: Monitoring MRD under targeted therapies - TBC
• Reliable vs unreliable molecular MRD biomarkers in AML - Christian Thiede, Dresden, DE

Poster Blitz presentations

Lunch and Poster session

Industry lecture(s)

• Recent advances on MRD monitoring in T-ALL by NGF - Lukasz Sedek, Zabrze, PL
• Single cell features of residual ALL cells - Sonja Bendig, Kiel, DE
• Immunotherapies in childhood ALL: Role of MRD and redefinition of risk stratification - Martin Schrappe, Kiel, DE
• MRD failure in predicting outcome in adult ALL: Do we need modified MRD methodologies - Emmanuelle Clappier, Paris, FR
• Abstract based presentation

Coffee break

• MRD monitoring in CLL by NGF vs NGS - Sebastian Böttcher, Rostock, DE
• Retrospective tracking subclones with high malignant potential in MBL, CLL & Richter transformation - Elias Campo, Barcelona, ES
• Clonal evolution under BTK and BCL2 inhibition - TBC
• MRD in CLL as surrogate marker for PFS, but also a surrogate for OS - Othman Al-Sawaf, Cologne, DE
• Abstract based presentation

Symposium dinner

• Role of ctDNA-based MRD in aggressive and indolent lymphomas - Mouhamad Khouja, Kiel, DE
• Spatial tumor heterogeneity and sampling bias - Daniela Drandi, Torino, IT
• Role of CAR-T cells, MRD and immune monitoring in diffuse large B cell - TBC
• Pro & Contra Debate: ctDNA versus PET-CT
• Abstract based presentation

Coffee break

• New response criteria in multiple myeloma - Shaji Kumar, Rochester, US
• Can mass spectrometry replace bone marrow monitoring in myeloma? - Noemi Puig, Salamanca, ES
• High-sensitive CTPC detection and immune monitoring in blood as new biomarkers - TBC
• Sustained MRD negativity in myeloma: The new goal for curative intent? - Jesus San Miguel, Pamplona, ES
• Abstract based presentation

Lunch and Poster session

• Immune reconstitution after modern therapies: Can we predict? - TBC
• T-CUS and MBL in the general population - Julia Almeida, Salamanca, ES
• Present and future of CAR cell-based immunotherapies - Manel Juan, Barcelona, ES

Poster prize and Closing remarks

Coffee break

University Farewell Lecture Jacques J.M. van Dongen: History of MRD diagnostics: Lessons from 40 years of MRD studies: Role of collaboration

Reception and drinks